The Approval Process in Action

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.

Biotech Company Reports Promising Neurological Treatment in Clinical Study
Source: Streetwise Reports (04/25/2025)

Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year.

Explorer Uncovers Massive Gold-Antimony Zone in Nevada
Source: Streetwise Reports (04/25/2025)

NevGold Corp. (NAU:TSX.V; NAUFF:OTC; 5E50:FSE) reported standout gold-antimony results at its Limousine Butte Project in Nevada, including 7.12 g/t AuEq over 16.8 meters. Read more on new targets.

Tungsten Explorer Targets Big Gains in Portugal Projects
Source: Streetwise Reports (04/25/2025)

Allied Critical Metals Inc. company discovers high-grade tungsten at two historical sites in Portugal, aiming for near-term production and long-term market impact. Read about the company's plans ahead of its public debut.

AbraSilver Resource Corp. (ABRA:TSX; ABBRF:OTCQX) hit 621m of copper-gold-molybdenum mineralization in Argentina's San Juan Province, confirming a large-scale porphyry system with strong upside. Read more about how this drill success could reshape resource potential at La Coipita.

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Source: Streetwise Reports (04/24/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company.